Advertisement
Advertisement
U.S. Markets open in 3 hrs 9 mins
Advertisement
Advertisement
Advertisement
Advertisement

Akebia Therapeutics, Inc. (AKBA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.7100-0.0900 (-3.21%)
At close: 04:00PM EST
2.7300 +0.02 (+0.74%)
After hours: 07:29PM EST
Advertisement

Akebia Therapeutics, Inc.

245 First Street
Suite 1400
Cambridge, MA 02142
United States
617 871 2098
http://www.akebia.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees379

Key Executives

NameTitlePayExercisedYear Born
Mr. John P. Butler MBACEO, Pres & Director1.2MN/A1964
Mr. David A. SpellmanSr. VP, CFO & Treasurer591.06kN/A1977
Mr. Michel DahanSr. VP & COO655.14kN/A1979
Mr. Jason A. AmelloExec. Officer435.66kN/A1968
Mr. Dell FaulkinghamSr. VP & Chief Commercial Officer660.04kN/A1973
Dr. Steven Keith BurkeSr. VP of R&D and Chief Medical Officer681.87kN/A1961
Ms. Violetta CotreauSr. VP, Chief Accounting Officer & Principal Accounting OfficerN/AN/A1973
Ms. Nicole R. HadasSr. VP, Chief Legal Officer & Sec.N/AN/A1973
Mr. Douglas JermasekVP of Marketing & StrategyN/AN/AN/A
Ms. Tamara DillonSr. VP of HRN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Akebia Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement